Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7E7E

The co-crystal structure of ACE2 with Fab

Summary for 7E7E
Entry DOI10.2210/pdb7e7e/pdb
DescriptorProcessed angiotensin-converting enzyme 2, h11B11-Fab, ZINC ION, ... (4 entities in total)
Functional Keywordsace2 fab, antiviral protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains6
Total formula weight237932.69
Authors
Xiao, J.Y.,Zhang, Y. (deposition date: 2021-02-26, release date: 2021-07-14, Last modification date: 2024-11-20)
Primary citationDu, Y.,Shi, R.,Zhang, Y.,Duan, X.,Li, L.,Zhang, J.,Wang, F.,Zhang, R.,Shen, H.,Wang, Y.,Wu, Z.,Peng, Q.,Pan, T.,Sun, W.,Huang, W.,Feng, Y.,Feng, H.,Xiao, J.,Tan, W.,Wang, Y.,Wang, C.,Yan, J.
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.
Nat Commun, 12:5000-5000, 2021
Cited by
PubMed Abstract: The successive emergences and accelerating spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages and evolved resistance to some ongoing clinical therapeutics increase the risks associated with the coronavirus disease 2019 (COVID-19) pandemic. An urgent intervention for broadly effective therapies to limit the morbidity and mortality of COVID-19 and future transmission events from SARS-related coronaviruses (SARSr-CoVs) is needed. Here, we isolate and humanize an angiotensin-converting enzyme-2 (ACE2)-blocking monoclonal antibody (MAb), named h11B11, which exhibits potent inhibitory activity against SARS-CoV and circulating global SARS-CoV-2 lineages. When administered therapeutically or prophylactically in the hACE2 mouse model, h11B11 alleviates and prevents SARS-CoV-2 replication and virus-induced pathological syndromes. No significant changes in blood pressure and hematology chemistry toxicology were observed after injections of multiple high dosages of h11B11 in cynomolgus monkeys. Analysis of the structures of the h11B11/ACE2 and receptor-binding domain (RBD)/ACE2 complexes shows hindrance and epitope competition of the MAb and RBD for the receptor. Together, these results suggest h11B11 as a potential therapeutic countermeasure against SARS-CoV, SARS-CoV-2, and escape variants.
PubMed: 34404805
DOI: 10.1038/s41467-021-25331-x
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.8 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon